{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T11:37:32Z","timestamp":1791632252975,"version":"4.3.4"},"reference-count":144,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T00:00:00Z","timestamp":1771459200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Addiction poses a major global public health challenge. It is characterized by high prevalence, chronic relapse and limited efficacy of available pharmacotherapies across different substance use disorders. Increasing evidence demonstrates that incretin-based therapies directly modulate metabolic signaling pathways that intercross with central reward and motivational circuits, including hypothalamic-mesolimbic networks and dopaminergic neurotransmission. As a result, agents such as glucagon-like peptide 1 receptor agonists, originally developed for the treatment of type 2 diabetes and obesity, are now being actively investigated for their role in addiction treatment. This narrative review summarizes the current knowledge on the role of incretin-based therapies in the neurobiology of addiction. Evidence from preclinical models and human studies supports the potential therapeutic effect of glucagon-like peptide 1 receptor agonists in the treatment of alcohol use disorder, nicotine dependence, and the administration of other psychoactive substances, including psychostimulants, opioids, and cannabinoids. Preclinical studies consistently demonstrate that glucagon-like peptide 1 receptor agonists reduce substance intake, attenuate reward-related behaviors, and suppress relapse-like responding. So far, human evidence remains limited and is largely derived from observational studies. Preliminary research suggests potential reductions in substance use severity and overdose risk among individuals treated with incretin-based agents. While these findings highlight incretin signaling as a promising therapeutic option in addiction, the current evidence is insufficient to support their routine clinical use in the treatment of substance dependence. Therefore, further research is required to clarify underlying mechanisms and establish clinical efficacy. In particular, well-designed randomized controlled trials are needed to determine safety, tolerance and effectiveness of incretin-based therapies across different substance use disorders.<\/jats:p>","DOI":"10.3390\/jcm15041613","type":"journal-article","created":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T11:44:27Z","timestamp":1771501467000},"page":"1613","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Incretin-Based Therapies: A Novel Pathway in Addiction Treatment"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0260-8215","authenticated-orcid":false,"given":"Rosiejka","family":"Dawid","sequence":"first","affiliation":[{"name":"Department of Obesity Treatment, Metabolic Disorders and Clinical Dietetics, Poznan University of Medical Sciences, 61-701 Poznan, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7766-0654","authenticated-orcid":false,"given":"Micha\u0142owska","family":"Joanna","sequence":"additional","affiliation":[{"name":"Department of Obesity Treatment, Metabolic Disorders and Clinical Dietetics, Poznan University of Medical Sciences, 61-701 Poznan, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-8842-2251","authenticated-orcid":false,"given":"Marcickiewicz","family":"Justyna","sequence":"additional","affiliation":[{"name":"Department of Obesity Treatment, Metabolic Disorders and Clinical Dietetics, Poznan University of Medical Sciences, 61-701 Poznan, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-6997-8740","authenticated-orcid":false,"given":"Adela","family":"Bogda\u0144ska","sequence":"additional","affiliation":[{"name":"Medical Education, Wroclaw Medical University, 50-367 Wroclaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wiktoria","family":"B\u0142a\u017cejewska","sequence":"additional","affiliation":[{"name":"Department of Obesity Treatment, Metabolic Disorders and Clinical Dietetics, Poznan University of Medical Sciences, 61-701 Poznan, Poland"},{"name":"Doctoral School, Poznan University of Medical Sciences, 60-812 Poznan, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Szuli\u0144ska","sequence":"additional","affiliation":[{"name":"Department of Obesity Treatment, Metabolic Disorders and Clinical Dietetics, Poznan University of Medical Sciences, 61-701 Poznan, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,2,19]]},"reference":[{"key":"ref_1","unstructured":"World Health Organization (2025). WHO Global Report on Trends in Prevalence of Tobacco Use 2000\u20132024 and Projections 2025\u20132030, World Health Organization."},{"key":"ref_2","unstructured":"World Health Organization (2024). Global Status Report on Alcohol and Health and Treatment of Substance Use Disorders, World Health Organization."},{"key":"ref_3","unstructured":"UNODC (2024). World Drug Report 2024, UNODC. Available online: https:\/\/www.unodc.org\/unodc\/en\/data-and-analysis\/world-drug-report-2024.html."},{"key":"ref_4","unstructured":"(2025, December 28). World Drug Report-2025 Special Points of Interest. Available online: https:\/\/www.unodc.org\/unodc\/en\/data-and-analysis\/world-drug-report-2025-special-points-of-interest.html."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.drugalcdep.2011.09.002","article-title":"Tobacco, Alcohol, Cannabis and Other Illegal Drug Use among Young Adults: The Socioeconomic Context","volume":"121","author":"Redonnet","year":"2012","journal-title":"Drug Alcohol. Depend."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Nawi, A.M., Ismail, R., Ibrahim, F., Hassan, M.R., Manaf, M.R.A., Amit, N., Ibrahim, N., and Shafurdin, N.S. (2021). Risk and Protective Factors of Drug Abuse among Adolescents: A Systematic Review. BMC Public Health, 21.","DOI":"10.1186\/s12889-021-11906-2"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Morojele, N.K., Shenoi, S.V., Shuper, P.A., Braithwaite, R.S., and Rehm, J. (2021). Alcohol Use and the Risk of Communicable Diseases. Nutrients, 13.","DOI":"10.3390\/nu13103317"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.jhep.2022.08.030","article-title":"Alcohol Consumption and Metabolic Syndrome: Clinical and Epidemiological Impact on Liver Disease","volume":"78","author":"Byrne","year":"2023","journal-title":"J. Hepatol."},{"key":"ref_9","unstructured":"(2025, December 28). Agents Classified by the IARC Monographs. Available online: https:\/\/monographs.iarc.who.int\/agents-classified-by-the-iarc\/."},{"key":"ref_10","unstructured":"World Health Organization (2024). Illicit Trade of Tobacco in South-East Asia Region, World Health Organization, Regional Office for South-East Asia."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"102365","DOI":"10.1016\/j.canep.2023.102365","article-title":"The Cost of Premature Death from Cancer Attributable to Alcohol: Productivity Losses in Europe in 2018","volume":"84","author":"Rumgay","year":"2023","journal-title":"Cancer Epidemiol."},{"key":"ref_12","unstructured":"(2025, December 29). Economy\u2014Institute of Alcohol Studies. Available online: https:\/\/www.ias.org.uk\/factsheet\/economy\/."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"107626","DOI":"10.1016\/j.addbeh.2023.107626","article-title":"Engineered Highs: Reward Variability and Frequency as Potential Prerequisites of Behavioural Addiction","volume":"140","author":"Clark","year":"2023","journal-title":"Addict. Behav."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Marquez-Meneses, J.D., Olaya-Bonilla, S.A., Barrera-Carre\u00f1o, S., Tibaduiza-Ar\u00e9valo, L.C., Forero-C\u00e1rdenas, S., Carrillo-Vaca, L., Rojas-Rodr\u00edguez, L.C., Calderon-Ospina, C.A., and Rodr\u00edguez-Quintana, J. (2025). GLP-1 Analogues in the Neurobiology of Addiction: Translational Insights and Therapeutic Perspectives. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26115338"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"10383","DOI":"10.2147\/DDDT.S559919","article-title":"The Clinical Application of GLP-1RAs and GLP-1\/GIP Dual Receptor Agonists Based on Pharmacological Mechanisms: A Review","volume":"19","author":"Liu","year":"2025","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_16","first-page":"8","article-title":"Poll: Roughly 12% of US Adults Have Used a GLP-1 Drug, Even If Unaffordable","volume":"332","author":"Harris","year":"2024","journal-title":"JAMA"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Zhao, X., Wang, M., Wen, Z., Lu, Z., Cui, L., Fu, C., Xue, H., Liu, Y., and Zhang, Y. (2021). GLP-1 Receptor Agonists: Beyond Their Pancreatic Effects. Front. Endocrinol., 12.","DOI":"10.3389\/fendo.2021.721135"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1152\/ajplegacy.1930.91.2.649","article-title":"Studies on the Physiology of Secretin: III. Further Studies on the Effects of Secretin on the Blood Sugar","volume":"91","author":"Barre","year":"1930","journal-title":"Am. J. Physiol.-Leg. Content"},{"key":"ref_19","unstructured":"Labarre, J. (2025, December 28). Sur Les Possibilites d\u2019un Traitement Du Diabete Par I\u2019incretine. Available online: https:\/\/www.semanticscholar.org\/paper\/Sur-les-possibilites-d%27un-traitement-du-diabete-par-Labarre\/b4ea8ec486db924054d70827aed214da2b85c33f."},{"key":"ref_20","unstructured":"La Barre, J. (2025, December 28). La S\u00e9cr\u00e9tine: Son R\u00f4le Physiologique, Ses Propri\u00e9t\u00e9s Th\u00e9rapeutiques. Available online: https:\/\/www.amazon.fr\/Secretine-role-physiologique-proprietes-therapetiques\/dp\/B000IU6YIY#:~:text=Not%C3%A9%20\/5.%20Retrouvez%20La%20Secretine:%20Son%20role,stock%20sur%20Amazon.fr.%20Achetez%20neuf%20ou%20d'occasion."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1172\/JCI104130","article-title":"Immunoassay of Endogenous Plasma Insulin in Man","volume":"39","author":"Yalow","year":"1960","journal-title":"J. Clin. Investig."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/S0140-6736(64)90011-X","article-title":"New Interpretation of Oral Glucose Tolerance","volume":"284","author":"Mcintyre","year":"1964","journal-title":"Lancet"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1113\/jphysiol.1970.sp009155","article-title":"Further Purification of a Polypeptide Demonstrating Enterogastrone Activity","volume":"209","author":"Brown","year":"1970","journal-title":"J. Physiol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1139\/o71-122","article-title":"A Gastric Inhibitory Polypeptide II: The Complete Amino Acid Sequence","volume":"49","author":"Brown","year":"1971","journal-title":"Can. J. Biochem."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1210\/jcem-37-5-826","article-title":"Stimulation of Insulin Secretion by Gastric Inhibitory Polypeptide in Man","volume":"37","author":"Dupre","year":"1973","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1038\/304368a0","article-title":"Exon Duplication and Divergence in the Human Preproglucagon Gene","volume":"304","author":"Bell","year":"1983","journal-title":"Nature"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1038\/302716a0","article-title":"Hamster Preproglucagon Contains the Sequence of Glucagon and Two Related Peptides","volume":"302","author":"Bell","year":"1983","journal-title":"Nature"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"7402","DOI":"10.1016\/S0021-9258(18)42531-8","article-title":"Isolation and Characterization of Exendin-4, an Exendin-3 Analogue, from Heloderma Suspectum Venom. Further Evidence for an Exendin Receptor on Dispersed Acini from Guinea Pig Pancreas","volume":"267","author":"Eng","year":"1992","journal-title":"J. Biol. Chem."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0167-0115(96)00135-8","article-title":"Bioactive Peptides from Lizard Venoms","volume":"61","author":"Raufman","year":"1996","journal-title":"Regul. Pept."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/s41392-024-01931-z","article-title":"Glucagon-like Peptide-1 Receptor: Mechanisms and Advances in Therapy","volume":"9","author":"Zheng","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"101102","DOI":"10.1016\/j.molmet.2020.101102","article-title":"GLP-1 Receptor Agonists in the Treatment of Type 2 Diabetes\u2014State-of-the-Art","volume":"46","author":"Nauck","year":"2021","journal-title":"Mol. Metab."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Forzano, I., Varzideh, F., Avvisato, R., Jankauskas, S.S., Mone, P., and Santulli, G. (2022). Tirzepatide: A Systematic Update. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms232314631"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1007\/s12170-025-00770-z","article-title":"Triple Agonism Based Therapies for Obesity","volume":"19","author":"Goldney","year":"2025","journal-title":"Curr. Cardiovasc. Risk Rep."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Liu, Q.K. (2024). Mechanisms of Action and Therapeutic Applications of GLP-1 and Dual GIP\/GLP-1 Receptor Agonists. Front. Endocrinol., 15.","DOI":"10.3389\/fendo.2024.1431292"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/s41366-024-01473-y","article-title":"What Is the Pipeline for Future Medications for Obesity?","volume":"49","author":"Melson","year":"2025","journal-title":"Int. J. Obes."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.neuint.2019.04.010","article-title":"GLP-1: Molecular Mechanisms and Outcomes of a Complex Signaling System","volume":"128","author":"Smith","year":"2019","journal-title":"Neurochem. Int."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.molmet.2019.09.010","article-title":"Glucagon-like Peptide 1 (GLP-1)","volume":"30","author":"Finan","year":"2019","journal-title":"Mol. Metab."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"5","DOI":"10.2337\/diabetes.53.1.5","article-title":"Epac: A New cAMP-Binding Protein in Support of Glucagon-Like Peptide-1 Receptor-Mediated Signal Transduction in the Pancreatic \u03b2-Cell","volume":"53","author":"Holz","year":"2004","journal-title":"Diabetes"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"34","DOI":"10.2337\/db18-0317","article-title":"GLP-1 Receptor in Pancreatic \u03b1-Cells Regulates Glucagon Secretion in a Glucose-Dependent Bidirectional Manner","volume":"68","author":"Zhang","year":"2019","journal-title":"Diabetes"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"403","DOI":"10.2337\/db08-0792","article-title":"Somatostatin Secreted by Islet \u03b4-Cells Fulfills Multiple Roles as a Paracrine Regulator of Islet Function","volume":"58","author":"King","year":"2009","journal-title":"Diabetes"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1111\/bph.15603","article-title":"Reappraising the Role of the Vagus Nerve in GLP-1-mediated Regulation of Eating","volume":"179","author":"Brierley","year":"2022","journal-title":"Br. J. Pharmacol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1210\/jcem.87.3.8355","article-title":"Effects of Glucagon-Like Peptide 1 on Counterregulatory Hormone Responses, Cognitive Functions, and Insulin Secretion during Hyperinsulinemic, Stepped Hypoglycemic Clamp Experiments in Healthy Volunteers","volume":"87","author":"Nauck","year":"2002","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1191-e315","DOI":"10.1111\/j.1365-2982.2010.01554.x","article-title":"Differential Incretin Effects of GIP and GLP-1 on Gastric Emptying, Appetite, and Insulin-Glucose Homeostasis: Incretins, Gastric Emptying and Metabolic Control","volume":"22","author":"Edholm","year":"2010","journal-title":"Neurogastroenterol. Motil."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"34","DOI":"10.2337\/db15-0973","article-title":"Knockdown of GLP-1 Receptors in Vagal Afferents Affects Normal Food Intake and Glycemia","volume":"65","author":"Krieger","year":"2016","journal-title":"Diabetes"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"4059","DOI":"10.1210\/en.2007-1743","article-title":"Caudal Brainstem Processing Is Sufficient for Behavioral, Sympathetic, and Parasympathetic Responses Driven by Peripheral and Hindbrain Glucagon-like-Peptide-1 Receptor Stimulation","volume":"149","author":"Hayes","year":"2008","journal-title":"Endocrinology"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1530\/JOE-19-0007","article-title":"Impact of Exenatide on Mitochondrial Lipid Metabolism in Mice with Nonalcoholic Steatohepatitis","volume":"241","author":"Kalavalapalli","year":"2019","journal-title":"J. Endocrinol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"5916","DOI":"10.1523\/JNEUROSCI.5977-08.2009","article-title":"Direct Control of Peripheral Lipid Deposition by CNS GLP-1 Receptor Signaling Is Mediated by the Sympathetic Nervous System and Blunted in Diet-Induced Obesity","volume":"29","author":"Nogueiras","year":"2009","journal-title":"J. Neurosci."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"3346","DOI":"10.2337\/db14-0302","article-title":"GLP-1 Agonism Stimulates Brown Adipose Tissue Thermogenesis and Browning Through Hypothalamic AMPK","volume":"63","author":"Beiroa","year":"2014","journal-title":"Diabetes"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/s41569-023-00849-3","article-title":"Glucagon-like Peptide 1 Receptor Agonists: Cardiovascular Benefits and Mechanisms of Action","volume":"20","author":"Ussher","year":"2023","journal-title":"Nat. Rev. Cardiol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1186\/s12933-014-0142-7","article-title":"Cardiovascular Effects of Glucagon-like Peptide 1 (GLP-1) Receptor Agonists","volume":"13","author":"Saraiva","year":"2014","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_51","unstructured":"(2025, December 28). A Research Study to See How Semaglutide Works Compared to Placebo in People with Type 2 Diabetes and Chronic Kidney Disease (FLOW), Available online: https:\/\/clinicaltrials.gov\/study\/NCT03819153#publications."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Wici\u0144ski, M., Socha, M., Malinowski, B., W\u00f3dkiewicz, E., Walczak, M., G\u00f3rski, K., S\u0142upski, M., and Pawlak-Osi\u0144ska, K. (2019). Liraglutide and Its Neuroprotective Properties\u2014Focus on Possible Biochemical Mechanisms in Alzheimer\u2019s Disease and Cerebral Ischemic Events. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20051050"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.pcad.2024.12.010","article-title":"Anti-Consumption Agents: Tirzepatide and Semaglutide for Treating Obesity-Related Diseases and Addictions, and Improving Life Expectancy","volume":"89","author":"Franco","year":"2025","journal-title":"Prog. Cardiovasc. Dis."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1111\/bph.15677","article-title":"The Role of Glucagon-like Peptide 1 (GLP-1) in Addictive Disorders","volume":"179","author":"Klausen","year":"2022","journal-title":"Br. J. Pharmacol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"e170671","DOI":"10.1172\/jci.insight.170671","article-title":"The Glucagon-like Peptide-1 (GLP-1) Analogue Semaglutide Reduces Alcohol Drinking and Modulates Central GABA Neurotransmission","volume":"8","author":"Chuong","year":"2023","journal-title":"JCI Insight"},{"key":"ref_56","unstructured":"World Health Organization (2018). Global Status Report on Alcohol and Health 2018, World Health Organization."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/S0140-6736(19)31775-1","article-title":"Alcohol Use Disorders","volume":"394","author":"Carvalho","year":"2019","journal-title":"Lancet"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1017\/S0033291716002841","article-title":"A Meta-Analysis of Acute Use of Alcohol and the Risk of Suicide Attempt","volume":"47","author":"Borges","year":"2017","journal-title":"Psychol. Med."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"e70004","DOI":"10.1111\/bcpt.70004","article-title":"Effects of GLP-1 Receptor Agonists in Alcohol Use Disorder","volume":"136","author":"Klausen","year":"2025","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"ref_60","unstructured":"National Institute for Health and Care Excellence (NICE) (2014). Alcohol-Use Disorders: Diagnosis, Assessment and Management of Harmful Drinking (High-Risk Drinking) and Alcohol Dependence: Clinical Guideline, National Institute for Health and Care Excellence (NICE)."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1001\/jama.2018.11406","article-title":"Diagnosis and Pharmacotherapy of Alcohol Use Disorder: A Review","volume":"320","author":"Kranzler","year":"2018","journal-title":"JAMA"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1111\/adb.12295","article-title":"The Glucagon-like Peptide 1 Receptor Agonist Liraglutide Attenuates the Reinforcing Properties of Alcohol in Rodents","volume":"21","author":"Maccioni","year":"2016","journal-title":"Addict. Biol."},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Marty, V.N., Farokhnia, M., Munier, J.J., Mulpuri, Y., Leggio, L., and Spigelman, I. (2020). Long-Acting Glucagon-Like Peptide-1 Receptor Agonists Suppress Voluntary Alcohol Intake in Male Wistar Rats. Front. Neurosci., 14.","DOI":"10.3389\/fnins.2020.599646"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1016\/j.psyneuen.2012.11.009","article-title":"The Glucagon-like Peptide 1 Analogue Exendin-4 Attenuates Alcohol Mediated Behaviors in Rodents","volume":"38","author":"Egecioglu","year":"2013","journal-title":"Psychoneuroendocrinology"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1111\/acer.13199","article-title":"Effects of the GLP-1 Agonist Exendin-4 on Intravenous Ethanol Self-Administration in Mice","volume":"40","author":"Caine","year":"2016","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.pbb.2017.07.014","article-title":"The Glucagon-like Peptide 1 Receptor Agonist Exendin-4 Decreases Relapse-like Drinking in Socially Housed Mice","volume":"160","author":"Thomsen","year":"2017","journal-title":"Pharmacol. Biochem. Behav."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"114249","DOI":"10.1016\/j.bbr.2022.114249","article-title":"Mesolimbic Exendin-4 Attenuates Reward Salience Evoked by Neuropeptide Y and Ghrelin","volume":"440","author":"Brigande","year":"2023","journal-title":"Behav. Brain Res."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"ENEURO.0443-18.2019","DOI":"10.1523\/ENEURO.0443-18.2019","article-title":"Glucagon-Like Peptide-1 Receptor Agonist Treatment Does Not Reduce Abuse-Related Effects of Opioid Drugs","volume":"6","author":"Bornebusch","year":"2019","journal-title":"eNeuro"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1007\/s00213-023-06367-x","article-title":"Sex-Dependent Divergence in the Effects of GLP-1 Agonist Exendin-4 on Alcohol Reinforcement and Reinstatement in C57BL\/6J Mice","volume":"240","author":"Thomsen","year":"2023","journal-title":"Psychopharmacology"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"104642","DOI":"10.1016\/j.ebiom.2023.104642","article-title":"Semaglutide Reduces Alcohol Intake and Relapse-like Drinking in Male and Female Rats","volume":"93","author":"Edvardsson","year":"2023","journal-title":"eBioMedicine"},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Aran\u00e4s, C., Blid Sk\u00f6ldheden, S., and Jerlhag, E. (2023). Antismoking Agents Do Not Contribute Synergistically to Semaglutide\u2019s Ability to Reduce Alcohol Intake in Rats. Front. Pharmacol., 14.","DOI":"10.3389\/fphar.2023.1180512"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s00213-024-06637-2","article-title":"Effect of the Glucagon-like Peptide-1 (GLP-1) Receptor Agonist Semaglutide on Alcohol Consumption in Alcohol-Preferring Male Vervet Monkeys","volume":"242","author":"Klausen","year":"2025","journal-title":"Psychopharmacology"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1038\/s41398-020-00923-1","article-title":"Long-Term Treatment with a Glucagon-like Peptide-1 Receptor Agonist Reduces Ethanol Intake in Male and Female Rats","volume":"10","author":"Kalafateli","year":"2020","journal-title":"Transl. Psychiatry"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"bqaf028","DOI":"10.1210\/endocr\/bqaf028","article-title":"GLP-1 Receptor Agonists: Promising Therapeutic Targets for Alcohol Use Disorder","volume":"166","author":"Jerlhag","year":"2025","journal-title":"Endocrinology"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1007\/s11064-023-04093-6","article-title":"Liraglutide Reduces Alcohol Consumption, Anxiety, Memory Impairment, and Synapse Loss in Alcohol Dependent Mice","volume":"49","author":"Liu","year":"2024","journal-title":"Neurochem. Res."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1007\/s11011-014-9627-z","article-title":"Glucagon-like Peptide-1 (GLP-1) Receptor Agonist Prevents Development of Tolerance to Anti-Anxiety Effect of Ethanol and Withdrawal-Induced Anxiety in Rats","volume":"30","author":"Sharma","year":"2015","journal-title":"Metab. Brain Dis."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1007\/s11011-014-9603-7","article-title":"Dipeptidyl-Peptidase IV (DPP-IV) Inhibitor Delays Tolerance to Anxiolytic Effect of Ethanol and Withdrawal-Induced Anxiety in Rats","volume":"30","author":"Sharma","year":"2015","journal-title":"Metab. Brain Dis."},{"key":"ref_78","unstructured":"Kalra, S., Kalra, B., and Sharma, A. (2011, January 24\u201328). Change in Alcohol Consumption Following Liraglutide Initiation: A Real Life Experience. Presented at the 71st American Diabetes Association Conference, San Diego, CA, USA."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"e583","DOI":"10.1038\/tp.2015.68","article-title":"The Glucagon-like Peptide-1 Receptor as a Potential Treatment Target in Alcohol Use Disorder: Evidence from Human Genetic Association Studies and a Mouse Model of Alcohol Dependence","volume":"5","author":"Suchankova","year":"2015","journal-title":"Transl. Psychiatry"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"13027","DOI":"10.1038\/s41598-022-17190-3","article-title":"Differential Association between the GLP1R Gene Variants and Brain Functional Connectivity According to the Severity of Alcohol Use","volume":"12","author":"Farokhnia","year":"2022","journal-title":"Sci. Rep."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"e159863","DOI":"10.1172\/jci.insight.159863","article-title":"Exenatide Once Weekly for Alcohol Use Disorder Investigated in a Randomized, Placebo-Controlled Clinical Trial","volume":"7","author":"Klausen","year":"2022","journal-title":"JCI Insight"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"e170419","DOI":"10.1172\/jci.insight.170419","article-title":"Effects of Dulaglutide on Alcohol Consumption during Smoking Cessation","volume":"8","author":"Probst","year":"2023","journal-title":"JCI Insight"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1001\/jamapsychiatry.2024.4789","article-title":"Once-Weekly Semaglutide in Adults With Alcohol Use Disorder: A Randomized Clinical Trial","volume":"82","author":"Hendershot","year":"2025","journal-title":"JAMA Psychiatry"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"23m15068","DOI":"10.4088\/JCP.23m15068","article-title":"Significant Decrease in Alcohol Use Disorder Symptoms Secondary to Semaglutide Therapy for Weight Loss: A Case Series","volume":"85","author":"Richards","year":"2023","journal-title":"J. Clin. Psychiatry"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1111\/bcpt.13776","article-title":"Use of GLP-1 Receptor Agonists and Subsequent Risk of Alcohol-related Events. A Nationwide Register-based Cohort and Self-controlled Case Series Study","volume":"131","author":"Rungby","year":"2022","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"4548","DOI":"10.1038\/s41467-024-48780-6","article-title":"Associations of Semaglutide with Incidence and Recurrence of Alcohol Use Disorder in Real-World Population","volume":"15","author":"Wang","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1111\/add.16679","article-title":"The Association between Glucose-dependent Insulinotropic Polypeptide and\/or Glucagon-like Peptide-1 Receptor Agonist Prescriptions and Substance-related Outcomes in Patients with Opioid and Alcohol Use Disorders: A Real-world Data Analysis","volume":"120","author":"Qeadan","year":"2025","journal-title":"Addiction"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1001\/jamapsychiatry.2024.3599","article-title":"Repurposing Semaglutide and Liraglutide for Alcohol Use Disorder","volume":"82","author":"Tiihonen","year":"2025","journal-title":"JAMA Psychiatry"},{"key":"ref_89","first-page":"5","article-title":"Social Media as Pharmacovigilance: The Potential for Patient Reports to Inform Clinical Research on Glucagon-like Peptide 1 (GLP-1) Receptor Agonists for Substance Use Disorders","volume":"85","author":"Bremmer","year":"2024","journal-title":"J. Stud. Alcohol. Drugs"},{"key":"ref_90","doi-asserted-by":"crossref","unstructured":"Arillotta, D., Floresta, G., Papanti Pelletier, G.D., Guirguis, A., Corkery, J.M., Martinotti, G., and Schifano, F. (2024). Exploring the Potential Impact of GLP-1 Receptor Agonists on Substance Use, Compulsive Behavior, and Libido: Insights from Social Media Using a Mixed-Methods Approach. Brain Sci., 14.","DOI":"10.3390\/brainsci14060617"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"20998","DOI":"10.1038\/s41598-023-48267-2","article-title":"Semaglutide and Tirzepatide Reduce Alcohol Consumption in Individuals with Obesity","volume":"13","author":"Quddos","year":"2023","journal-title":"Sci. Rep."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"112840","DOI":"10.1016\/j.drugalcdep.2025.112840","article-title":"Impact of Glucagon-like Peptide-1 Receptor Agonists on Alcohol Consumption and Liver-Related Outcomes: A Systematic Review and Meta-Analysis","volume":"275","author":"Silveira","year":"2025","journal-title":"Drug Alcohol. Depend."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1016\/S0140-6736(21)01169-7","article-title":"Spatial, Temporal, and Demographic Patterns in Prevalence of Smoking Tobacco Use and Attributable Disease Burden in 204 Countries and Territories, 1990\u20132019: A Systematic Analysis from the Global Burden of Disease Study 2019","volume":"397","author":"Reitsma","year":"2021","journal-title":"Lancet"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"e067582","DOI":"10.1136\/bmj-2021-067582","article-title":"Patterns of Tobacco Use in Low and Middle Income Countries by Tobacco Product and Sociodemographic Characteristics: Nationally Representative Survey Data from 82 Countries","volume":"378","author":"Theilmann","year":"2022","journal-title":"BMJ"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.7326\/M23-2718","article-title":"Association of Semaglutide with Tobacco Use Disorder in Patients with Type 2 Diabetes: Target Trial Emulation Using Real-World Data","volume":"177","author":"Wang","year":"2024","journal-title":"Ann. Intern. Med."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1093\/ntr\/nty259","article-title":"A Machine-Learning Approach to Predicting Smoking Cessation Treatment Outcomes","volume":"22","author":"Coughlin","year":"2020","journal-title":"Nicotine Tob. Res."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1093\/ntr\/ntab066","article-title":"Exenatide Adjunct to Nicotine Patch Facilitates Smoking Cessation and May Reduce Post-Cessation Weight Gain: A Pilot Randomized Controlled Trial","volume":"23","author":"Yammine","year":"2021","journal-title":"Nicotine Tob. Res."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"103363","DOI":"10.1016\/j.eclinm.2025.103363","article-title":"The Expanding Role of GLP-1 Receptor Agonists: A Narrative Review of Current Evidence and Future Directions","volume":"86","author":"Moiz","year":"2025","journal-title":"eClinicalMedicine"},{"key":"ref_99","doi-asserted-by":"crossref","unstructured":"Al Qassab, M., Mneimneh, M., Jradi, A., Derbas, B., Dabboussi, D., Khoury Baini, J., Katrib, N., Chaarani, N., Attieh, P., and Kanaan, A. (2025). The Expanding Role of GLP-1 Receptor Agonists: Advancing Clinical Outcomes in Metabolic and Mental Health. Curr. Issues Mol. Biol., 47.","DOI":"10.3390\/cimb47040285"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"114565","DOI":"10.1016\/j.physbeh.2024.114565","article-title":"Targeting GLP-1 Receptors to Reduce Nicotine Use Disorder: Preclinical and Clinical Evidence","volume":"281","author":"Herman","year":"2024","journal-title":"Physiol. Behav."},{"key":"ref_101","doi-asserted-by":"crossref","unstructured":"Egecioglu, E., Engel, J.A., and Jerlhag, E. (2013). The Glucagon-Like Peptide 1 Analogue Exendin-4 Attenuates the Nicotine-Induced Locomotor Stimulation, Accumbal Dopamine Release, Conditioned Place Preference as Well as the Expression of Locomotor Sensitization in Mice. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0077284"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1007\/s00213-023-06376-w","article-title":"Liraglutide Attenuates Nicotine Self-Administration as Well as Nicotine Seeking and Hyperphagia during Withdrawal in Male and Female Rats","volume":"240","author":"Herman","year":"2023","journal-title":"Psychopharmacology"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1038\/nn.4540","article-title":"GLP-1 Acts on Habenular Avoidance Circuits to Control Nicotine Intake","volume":"20","author":"Tuesta","year":"2017","journal-title":"Nat. Neurosci."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"102429","DOI":"10.1016\/j.eclinm.2024.102429","article-title":"Effect of Dulaglutide in Promoting Abstinence during Smoking Cessation: 12-Month Follow-up of a Single-Centre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Trial","volume":"68","author":"Lengsfeld","year":"2024","journal-title":"eClinicalMedicine"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"109407","DOI":"10.1016\/j.neuropharm.2022.109407","article-title":"Neural Circuits Controlling Choice Behavior in Opioid Addiction","volume":"226","author":"Chang","year":"2023","journal-title":"Neuropharmacology"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1152\/physrev.00014.2018","article-title":"The Neuroscience of Drug Reward and Addiction","volume":"99","author":"Volkow","year":"2019","journal-title":"Physiol. Rev."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.orcp.2020.02.004","article-title":"Food Cue Recruits Increased Reward Processing and Decreased Inhibitory Control Processing in the Obese\/Overweight: An Activation Likelihood Estimation Meta-Analysis of fMRI Studies","volume":"14","author":"Meng","year":"2020","journal-title":"Obes. Res. Clin. Pract."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.neubiorev.2018.07.017","article-title":"Hungry Brains: A Meta-Analytical Review of Brain Activation Imaging Studies on Food Perception and Appetite in Obese Individuals","volume":"94","author":"Devoto","year":"2018","journal-title":"Neurosci. Biobehav. Rev."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1016\/j.neuron.2025.03.010","article-title":"The Neurobiology of Overeating","volume":"113","author":"Stuber","year":"2025","journal-title":"Neuron"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"NS20210006","DOI":"10.1042\/NS20210006","article-title":"Molecular Mechanisms of Action of Stimulant Novel Psychoactive Substances That Target the High-Affinity Transporter for Dopamine","volume":"5","author":"Sahai","year":"2021","journal-title":"Neuronal Signal"},{"key":"ref_111","doi-asserted-by":"crossref","unstructured":"Loi, B., Sahai, M.A., De Luca, M.A., Shiref, H., and Opacka-Juffry, J. (2020). The Role of Dopamine in the Stimulant Characteristics of Novel Psychoactive Substances (NPS)\u2014Neurobiological and Computational Assessment Using the Case of Desoxypipradrol (2-DPMP). Front. Pharmacol., 11.","DOI":"10.3389\/fphar.2020.00806"},{"key":"ref_112","doi-asserted-by":"crossref","unstructured":"Egecioglu, E., Engel, J.A., and Jerlhag, E. (2013). The Glucagon-Like Peptide 1 Analogue, Exendin-4, Attenuates the Rewarding Properties of Psychostimulant Drugs in Mice. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0069010"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.physbeh.2015.06.013","article-title":"The Glucagon-like Peptide 1 (GLP-1) Receptor Agonist Exendin-4 Reduces Cocaine Self-Administration in Mice","volume":"149","author":"Reddy","year":"2015","journal-title":"Physiol. Behav."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.physbeh.2012.03.014","article-title":"Exendin-4 Decreases Amphetamine-Induced Locomotor Activity","volume":"106","author":"Erreger","year":"2012","journal-title":"Physiol. Behav."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1038\/npp.2015.362","article-title":"Glucagon-Like Peptide-1 Receptor Activation in the Ventral Tegmental Area Decreases the Reinforcing Efficacy of Cocaine","volume":"41","author":"Schmidt","year":"2016","journal-title":"Neuropsychopharmacology"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"eadr5051","DOI":"10.1126\/sciadv.adr5051","article-title":"An Endogenous GLP- 1 Circuit Engages VTA GABA Neurons to Regulate Mesolimbic Dopamine Neurons and Attenuate Cocaine Seeking","volume":"11","author":"Merkel","year":"2025","journal-title":"Sci. Adv."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"4394","DOI":"10.1038\/s41380-020-00957-3","article-title":"GLP-1 Receptor Signaling in the Laterodorsal Tegmental Nucleus Attenuates Cocaine Seeking by Activating GABAergic Circuits That Project to the VTA","volume":"26","author":"Hernandez","year":"2021","journal-title":"Mol. Psychiatry"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1038\/s41386-018-0010-3","article-title":"Glucagon-like Peptide-1 Receptor Activation in the Ventral Tegmental Area Attenuates Cocaine Seeking in Rats","volume":"43","author":"Hernandez","year":"2018","journal-title":"Neuropsychopharmacology"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1111\/adb.12583","article-title":"Activation of Glucagon-like Peptide-1 Receptors in the Nucleus Accumbens Attenuates Cocaine Seeking in Rats","volume":"24","author":"Hernandez","year":"2019","journal-title":"Addict. Biol."},{"key":"ref_120","doi-asserted-by":"crossref","unstructured":"Zhu, C., Wang, L., Ding, J., Li, H., Wan, D., Sun, Y., Guo, B., He, Z., Ren, X., and Jiang, S. (2022). Effects of Glucagon-Like Peptide-1 Receptor Agonist Exendin-4 on the Reinstatement of Cocaine-Mediated Conditioned Place Preference in Mice. Front. Behav. Neurosci., 15.","DOI":"10.3389\/fnbeh.2021.769664"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"e809","DOI":"10.1038\/tp.2016.86","article-title":"Glucagon-like Peptide 1 Receptor Activation Regulates Cocaine Actions and Dopamine Homeostasis in the Lateral Septum by Decreasing Arachidonic Acid Levels","volume":"6","author":"Reddy","year":"2016","journal-title":"Transl. Psychiatry"},{"key":"ref_122","first-page":"1","article-title":"Semaglutide Suppresses Cocaine Taking, Seeking, and Cocaine-Evoked Dopamine Levels in the Nucleus Accumbens","volume":"98","author":"Caffrey","year":"2025","journal-title":"Eur. Neuropsychopharmacology"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1038\/mp.2014.177","article-title":"DAT Isn\u2019t All That: Cocaine Reward and Reinforcement Require Toll-like Receptor 4 Signaling","volume":"20","author":"Northcutt","year":"2015","journal-title":"Mol. Psychiatry"},{"key":"ref_124","doi-asserted-by":"crossref","unstructured":"Zhu, C., Tao, H., Rong, S., Xiao, L., Li, X., Jiang, S., Guo, B., Wang, L., Ding, J., and Gao, C. (2021). Glucagon-Like Peptide-1 Analog Exendin-4 Ameliorates Cocaine-Mediated Behavior by Inhibiting Toll-Like Receptor 4 Signaling in Mice. Front. Pharmacol., 12.","DOI":"10.3389\/fphar.2021.694476"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1097\/ADM.0000000000001147","article-title":"Feasibility of Exenatide, a GLP-1R Agonist, for Treating Cocaine Use Disorder: A Case Series Study","volume":"17","author":"Yammine","year":"2023","journal-title":"J. Addict. Med."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"108614","DOI":"10.1016\/j.drugalcdep.2021.108614","article-title":"Testing the Effects of the GLP-1 Receptor Agonist Exenatide on Cocaine Self-Administration and Subjective Responses in Humans with Cocaine Use Disorder","volume":"221","author":"Angarita","year":"2021","journal-title":"Drug Alcohol. Depend."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.neubiorev.2017.09.022","article-title":"Opioid-Induced Rewards, Locomotion, and Dopamine Activation: A Proposed Model for Control by Mesopontine and Rostromedial Tegmental Neurons","volume":"83","author":"Steidl","year":"2017","journal-title":"Neurosci. Biobehav. Rev."},{"key":"ref_128","first-page":"491","article-title":"A Brief Overview of the Neuropharmacology of Opioid Addiction","volume":"9","author":"Grothusen","year":"2022","journal-title":"Transl. Perioper. Pain Med."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/s41386-019-0531-4","article-title":"Activation of GLP-1 Receptors Attenuates Oxycodone Taking and Seeking without Compromising the Antinociceptive Effects of Oxycodone in Rats","volume":"45","author":"Zhang","year":"2020","journal-title":"Neuropsychopharmacology"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"e13117","DOI":"10.1111\/adb.13117","article-title":"Glucagon-like Peptide-1 Receptor Agonist, Liraglutide, Reduces Heroin Self-administration and Drug-induced Reinstatement of Heroin-seeking Behaviour in Rats","volume":"27","author":"Douton","year":"2022","journal-title":"Addict. Biol."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1097\/FBP.0000000000000685","article-title":"Acute Glucagon-like Peptide-1 Receptor Agonist Liraglutide Prevents Cue-, Stress-, and Drug-Induced Heroin-Seeking in Rats","volume":"33","author":"Douton","year":"2022","journal-title":"Behav. Pharmacol."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1097\/FBP.0000000000000609","article-title":"Glucagon-like Peptide-1 Receptor Agonist, Exendin-4, Reduces Reinstatement of Heroin-Seeking Behavior in Rats","volume":"32","author":"Douton","year":"2021","journal-title":"Behav. Pharmacol."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"108599","DOI":"10.1016\/j.neuropharm.2021.108599","article-title":"A Novel Dual Agonist of Glucagon-like Peptide-1 Receptors and Neuropeptide Y2 Receptors Attenuates Fentanyl Taking and Seeking in Male Rats","volume":"192","author":"Zhang","year":"2021","journal-title":"Neuropharmacology"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/s41386-024-01990-4","article-title":"Role of Dorsal Striatum Circuits in Relapse to Opioid Seeking after Voluntary Abstinence","volume":"50","author":"Ma","year":"2025","journal-title":"Neuropsychopharmacology"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"e2435247","DOI":"10.1001\/jamanetworkopen.2024.35247","article-title":"Semaglutide and Opioid Overdose Risk in Patients with Type 2 Diabetes and Opioid Use Disorder","volume":"7","author":"Wang","year":"2024","journal-title":"JAMA Netw. Open"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s13722-025-00618-2","article-title":"Efficacy of the GLP-1 Receptor Agonist, Semaglutide, in Abstinence from Illicit and Nonprescribed Opioids in an Outpatient Population with OUD: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial Protocol","volume":"20","author":"Freet","year":"2025","journal-title":"Addict. Sci. Clin. Pract."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s13722-024-00481-7","article-title":"Ecological Momentary Assessment and Cue-Elicited Drug Craving as Primary Endpoints: Study Protocol for a Randomized, Double-Blind, Placebo-Controlled Clinical Trial Testing the Efficacy of a GLP-1 Receptor Agonist in Opioid Use Disorder","volume":"19","author":"Freet","year":"2024","journal-title":"Addict. Sci. Clin. Pract."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"415","DOI":"10.2337\/db20-0162","article-title":"CB1 and GLP-1 Receptors Cross Talk Provides New Therapies for Obesity","volume":"70","author":"Zizzari","year":"2021","journal-title":"Diabetes"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.biopsych.2018.04.018","article-title":"The Lateral Habenula Directs Coping Styles Under Conditions of Stress via Recruitment of the Endocannabinoid System","volume":"84","author":"Berger","year":"2018","journal-title":"Biol. Psychiatry"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.bbr.2013.03.015","article-title":"Involvement of CB1 Receptors in the Ventral Tegmental Area in the Potentiation of Morphine Rewarding Properties in Acquisition but Not Expression in the Conditioned Place Preference Model","volume":"247","author":"Pahlevani","year":"2013","journal-title":"Behav. Brain Res."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.1523\/JNEUROSCI.2180-18.2019","article-title":"Chronic Suppression of Glucagon-Like Peptide-1 Receptor (GLP1R) mRNA Translation in the Rat Bed Nucleus of the Stria Terminalis Reduces Anxiety-Like Behavior and Stress-Induced Hypophagia, But Prolongs Stress-Induced Elevation of Plasma Corticosterone","volume":"39","author":"Zheng","year":"2019","journal-title":"J. Neurosci."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"14302","DOI":"10.1074\/jbc.M115.655662","article-title":"Modulation of Glucagon-like Peptide-1 (GLP-1) Potency by Endocannabinoid-like Lipids Represents a Novel Mode of Regulating GLP-1 Receptor Signaling","volume":"290","author":"Cheng","year":"2015","journal-title":"J. Biol. Chem."},{"key":"ref_143","first-page":"1","article-title":"Blockade of Cannabinoid 1 Receptor Improves GLP-1R Mediated Insulin Secretion in Mice","volume":"423","author":"Kim","year":"2016","journal-title":"Mol. Cell. Endocrinol."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1038\/s41380-024-02498-5","article-title":"Association of Semaglutide with Reduced Incidence and Relapse of Cannabis Use Disorder in Real-World Populations: A Retrospective Cohort Study","volume":"29","author":"Wang","year":"2024","journal-title":"Mol. Psychiatry"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/4\/1613\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T11:53:59Z","timestamp":1771502039000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/4\/1613"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,19]]},"references-count":144,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,2]]}},"alternative-id":["jcm15041613"],"URL":"https:\/\/doi.org\/10.3390\/jcm15041613","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,19]]}}}